CONTRACT TITLE - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
CONTRACT TITLE - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
批准号:
10045660
负责人:
SEEMA KHAN
金额:
$63.8万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-23 至 2020-09-22
关键词:
BiologicalClinicalClinical ChemopreventionClinical ResearchClinical TrialsConduct Clinical TrialsContractorContractsDataDevelopmentDivision of Cancer PreventionDrug IndustryFundingGuidelinesIndividualInfrastructureMaintenanceMalignant NeoplasmsMolecular TargetMonitorNational Cancer InstituteOutcomePerformancePhasePreventionPreventiveProgram DevelopmentSafetySiteVisitcancer preventionclinically relevantdata managementinterestlaboratory experimentmeetingsprevention clinical trialprograms
中文摘要
美国国家癌症研究所(NCI)癌症预防部(DCP)的0/I/II期癌症预防临床试验项目支持早期临床试验,以快速评估DCP感兴趣的癌症预防剂的临床活性和生物学效应。研究的药剂应包括制药行业自行开发并提供给DCP合作开发的药剂、市售药剂和DCP自行开发的药剂。本任务令的目标是提供核心基础设施,以支持临床试验的进行。
英文摘要
The National Cancer Institute (NCI), Division of Cancer Prevention (DCP) Phase 0/I/II Cancer Prevention Clinical Trials Program supports early clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents of interest to DCP. The agents to be studied shall include agents developed by the pharmaceutical industry and provided to DCP for collaborative development, commercially available agents, and agents developed by DCP. The objectives of this Task Order are to provide the core infrastructure to support the conduct of the clinical trials.
The Contractor shall conduct early clinical trials (Phase 0, I, and II) of DCP-sponsored agents, evaluate biologic effects of these agents on their molecular targets, evaluate other relevant biologic effects, and determine clinically relevant outcomes/correlates. This Task Order calls for the maintenance of the administrative core infrastructure to support the clinical and laboratory activities. These activities include but are not limited to: a. Maintaining the infrastructure to conduct and complete Early Phase Chemoprevention Clinical Trials. b) Revising the Data and Safety Monitoring Plan and Multi-Institutional Monitoring Plan plans as required for DCP approval, following guidelines established in the DCP approved plans, in order to support the conduct of NCI clinical trials. See http://prevention.cancer.gov/clinicaltrials/management/consortia. c) Serving as the liaison between DCP, NCI and sub-contractors performing individual clinical trials. d) Monitoring the performance of individual studies both remotely and via on-site monitoring visits. e) Providing data management to support trial conduct. f) Participating in annual meetings – i.e. Scientific and I-SCORE Individual clinical trials shall be funded under separate Task Orders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CONTRACT TITLE - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
-
批准号:10223848
-
项目类别:
-
资助金额:$63.74万
-
财政年份:2020
-
负责人:SEEMA KHAN
-
依托单位:
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
-
批准号:10452466
-
项目类别:
-
资助金额:$42.68万
-
财政年份:2019
-
负责人:SEEMA KHAN
-
依托单位:
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
-
批准号:10894578
-
项目类别:
-
资助金额:$7.3万
-
财政年份:2019
-
负责人:SEEMA KHAN
-
依托单位:
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
-
批准号:9369089
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER
-
批准号:9915354
-
项目类别:
-
资助金额:$5.74万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
IGF::OT::IGF PHASE IIB TRIAL OF NEOADJUVANT ORAL TAMOXIFEN VERSUS TRANSDERMAL 4-HYDROXYTAMOXIFEN IN WOMEN WITH DCIS OF THE BREAST
-
批准号:9369106
-
项目类别:
-
资助金额:$63.02万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
-
批准号:10018590
-
项目类别:
-
资助金额:$14.82万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
-
批准号:10408643
-
项目类别:
-
资助金额:$22.68万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
-
批准号:10074464
-
项目类别:
-
资助金额:$60.07万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER
-
批准号:9369104
-
项目类别:
-
资助金额:$62.64万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
PHASE IIB TRIAL OF NEOADJUVANT ORAL TAMOXIFEN VERSUS TRANSDERMAL 4-HYDROXYTAMOXIFEN IN WOMEN WITH DCIS OF THE BREAST
-
批准号:10018597
-
项目类别:
-
资助金额:$60.17万
-
财政年份:2016
-
负责人:SEEMA KHAN
-
依托单位:
CORE INFRASTRUCTURE SUPPORT
-
批准号:9511679
-
项目类别:
-
资助金额:$157.57万
-
财政年份:2015
-
负责人:SEEMA KHAN
-
依托单位:
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
-
批准号:31070748
-
项目类别:面上项目
-
资助金额:34.0万元
-
批准年份:2010
-
负责人:Christine Nardini
-
依托单位: